clinical trial · NCT06345482
A Study of MHB039A for Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd·phase2·active not recruiting·n = 196
Advanced Solid TumorMHB039A
brief summary
Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in advanced malignant tumors.
started
Apr 16, 2024
primary completion
Apr 1, 2028
completion
Jun 1, 2029
last updated
Nov 20, 2025
detailed description
This first-in-human, dose escalation and dose expansion study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of MHB039A in patients with advanced solid tumor. The Phase I stage （dose escalation）is to determine the maximum tolerated dose (MTD). The phase II stage （dose expansion）is to determine the recommended Phase 2 dose (RP2D) according to safety and efficacy in specific tumor types.
official title
A Phase I/II Study of MHB039A for Advanced Solid Tumor to Evaluate the Efficacy and Safety
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol